MigraineMind research summary
PRT-064040: A nasal spray of novel, potent, and selective calcitonin gene-related peptide receptor antagonist for migraine.
J Pharmacol Exp Ther | 2026
Laboratory / animal studySummary
Calcitonin gene-related peptide, or CGRP, is linked to migraine and other conditions. Researchers developed a new nasal spray called PRT-064040. This drug acts as a CGRP receptor antagonist. It aims to meet the urgent needs of migraine treatment. In laboratory tests, PRT-064040 showed a strong attraction to the human CGRP receptor. It effectively blocked CGRP-induced reactions, demonstrating high potency. The study found that PRT-064040 was selective, not impacting similar receptors at high concentrations. Tests in monkeys showed that this spray reduced CGRP-related blood flow issues. After nasal administration in rats, PRT-064040 was absorbed quickly. Its effects peaked within 10 to 15 minutes. This research indicates that PRT-064040 has the potential to act quickly and efficiently. It may also lessen the chance of side effects during treatment. Overall, PRT-064040 represents a promising advance in migraine therapy. Clinical relevance: This research suggests that PRT-064040 could provide rapid relief for migraine patients, potentially improving treatment experiences and outcomes.
Key Learning Points
- PRT-064040 is a new nasal spray designed to quickly relieve migraine symptoms by targeting the CGRP receptor.
- In laboratory tests, PRT-064040 showed strong effectiveness in blocking reactions linked to CGRP.
- The nasal spray was absorbed rapidly, with effects peaking within 10 to 15 minutes after administration.
- This treatment may reduce the likelihood of side effects compared to other migraine therapies.
- Overall, PRT-064040 represents a significant advancement in the management of migraines, potentially enhancing patient outcomes.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.